Amplia Therapeutics (ASX:ATX) Total Liabilities : A$2.81 Mil (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Amplia Therapeutics Total Liabilities?

Amplia Therapeutics's Total Liabilities for the quarter that ended in Sep. 2023 was A$2.81 Mil.

Amplia Therapeutics's quarterly Total Liabilities increased from Sep. 2022 (A$2.80 Mil) to Mar. 2023 (A$2.85 Mil) but then declined from Mar. 2023 (A$2.85 Mil) to Sep. 2023 (A$2.81 Mil).

Amplia Therapeutics's annual Total Liabilities increased from Mar. 2021 (A$0.54 Mil) to Mar. 2022 (A$2.64 Mil) and increased from Mar. 2022 (A$2.64 Mil) to Mar. 2023 (A$2.85 Mil).

Amplia Therapeutics Total Liabilities Historical Data

The historical data trend for Amplia Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Total Liabilities Chart

Amplia Therapeutics Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

0.51

0.54

2.64

2.85

3.43

Amplia Therapeutics Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Total Liabilities	Get a 7-Day Free Trial															2.64	2.80	2.85	2.81	3.43

Amplia Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Amplia Therapeutics's Total Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.751	+	(0.095	+	0.0030000000000003
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.85

Total Liabilities	=	Total Assets (A: Mar. 2023 )	-	Total Equity (A: Mar. 2023 )
	=	18.684	-	15.836
	=	2.85

Amplia Therapeutics's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.746	+	(0.055	+	0.0059999999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.81

Total Liabilities	=	Total Assets (Q: Sep. 2023 )	-	Total Equity (Q: Sep. 2023 )
	=	17.559	-	14.753
	=	2.81

Amplia Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (ASX:ATX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (ASX:ATX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

INNMF:USA

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (ASX:ATX) Headlines

No Headlines